Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Obsidian Therapeutics Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are divided among 2 distinct examiners and 2 distinct art units. The involvement of 2 distinct examiners and 2 distinct art units indicates that the company's pending applications are being reviewed in separate administrative silos. This separation suggests that the 2 pending office actions may involve different technical aspects of the biotechnology field, requiring distinct prosecution strategies for each application.
VIVLEMORE, TRACY ANN is the busiest examiner, with 1 pending office action. With 2 distinct examiners each responsible for a single action, the prosecution workload is evenly distributed. The company must navigate the specific preferences of 2 distinct art units to advance its 2 pending office actions. This prosecution profile shows a clear division of labor at the patent office regarding the company's current applications within the Biotechnology & Pharmaceuticals area, as each of the 2 pending office actions is handled by a different examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18501621 | ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER | VIVLEMORE, TRACY ANN | 1638 | §112Other | Final Rejection | 30d overdue | Pending | Nov 03, 2023 |
| 18261765 | TUMOR-INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 AND USES THEREOF | XIAO, YAN | 1642 | §103DP | Non-Final OA | — | Pending | Jul 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial